Theradiag SA Total Liabilities
Theradiag SA total liabilities. Based on the latest financial reports, Theradiag SA (ALTHE) has total liabilities worth €14.09 Million EUR (≈ $16.47 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check ALTHE asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Theradiag SA (2001–2024)
Total liabilities of Theradiag SA from 2001 to 2024. This chart illustrates how Theradiag SA's total liabilities have evolved over time, based on quarterly financial data. Explore ALTHE long-term investments to assets to see how much of total assets are deployed in long-term investments.
Theradiag SA Competitors by Total Liabilities
The table below lists competitors of Theradiag SA ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Cellid Co. Ltd
KQ:299660
|
Korea | ₩36.66 Billion |
|
PBT Holdings Limited
JSE:PBT
|
South Africa | ZAC164.71 Million |
|
Cyclone Metals Ltd
AU:CLE
|
Australia | AU$1.18 Million |
|
HBR Realty Empreendimentos Imobiliários S.A
SA:HBRE3
|
Brazil | R$2.25 Billion |
|
Atakule Gayrimenkul Yatirim Ortakligi AS
IS:AGYO
|
Turkey | TL17.91 Million |
|
Singbao International Co Ltd
TWO:6130
|
Taiwan | NT$201.12 Million |
|
Oricom Inc
KQ:010470
|
Korea | ₩112.61 Billion |
|
Acorn Energy, Inc.
NASDAQ:ACFN
|
USA | $4.54 Million |
Liability Composition Analysis (2001–2024)
This chart breaks down Theradiag SA's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see ALTHE total asset value.
Liquidity & Leverage Metrics
Theradiag SA Total Liabilities Ratios Explained
Theradiag SA total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.40 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -5.55 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.22 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Theradiag SA's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Theradiag SA (2001–2024)
The table below shows the annual total liabilities of Theradiag SA from 2001 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €11.47 Million ≈ $13.41 Million |
-11.86% |
| 2023-12-31 | €13.01 Million ≈ $15.21 Million |
-2.90% |
| 2022-12-31 | €13.40 Million ≈ $15.66 Million |
+2.26% |
| 2021-12-31 | €13.10 Million ≈ $15.32 Million |
-4.95% |
| 2020-12-31 | €13.78 Million ≈ $16.12 Million |
+30.13% |
| 2019-12-31 | €10.59 Million ≈ $12.38 Million |
+4.91% |
| 2018-12-31 | €10.10 Million ≈ $11.80 Million |
-1.96% |
| 2017-12-31 | €10.30 Million ≈ $12.04 Million |
+12.77% |
| 2016-12-31 | €9.13 Million ≈ $10.68 Million |
+7.44% |
| 2015-12-31 | €8.50 Million ≈ $9.94 Million |
+54.25% |
| 2014-12-31 | €5.51 Million ≈ $6.44 Million |
-18.33% |
| 2013-12-31 | €6.75 Million ≈ $7.89 Million |
+132.77% |
| 2012-12-31 | €2.90 Million ≈ $3.39 Million |
+32.55% |
| 2011-12-31 | €2.19 Million ≈ $2.56 Million |
-16.97% |
| 2010-12-31 | €2.63 Million ≈ $3.08 Million |
-28.70% |
| 2009-12-31 | €3.69 Million ≈ $4.32 Million |
+354.93% |
| 2001-12-31 | €812.00K ≈ $949.31K |
-- |
About Theradiag SA
Theraclion SA provides therapeutic ultrasound equipment. It offers SONOVEIN, a robotic solution for the non-invasive echotherapy treatment of varicose veins; ECHOPULSE, a robotic and non-invasive solution for the echotherapy treatment of thyroid nodules and breast fibroadenoma; and EPack, a disposable that is installed on the device before treatment to protect the patient's skin and optimize imag… Read more